|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.470 AUD | -0.73% |
|
0.00% | -24.00% |
| 28/04 | Clinuvel Pharmaceuticals plans level II ADR upgrade and Nasdaq listing as CUVL | RE |
| 28/04 | Clinuvel Pharmaceuticals Advances Nasdaq ADR Uplisting With US SEC Review Underway | MT |
| Capitalization | 481M 348M 298M 272M 258M 477M 33.23B 3.25B 1.26B 15.79B 1.3B 1.28B 54.96B | P/E ratio 2026 * |
13.4x | P/E ratio 2027 * | 12.6x |
|---|---|---|---|---|---|
| Enterprise value | 227M 164M 141M 129M 122M 226M 15.7B 1.54B 596M 7.46B 616M 603M 25.97B | EV / Sales 2026 * |
2.28x | EV / Sales 2027 * | 1.85x |
| Free-Float |
83.79% | Yield 2026 * |
0.64% | Yield 2027 * | 0.84% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 day | -0.73% | ||
| Current month | +3.84% | ||
| 1 month | +3.61% | ||
| 3 months | -20.15% | ||
| 6 months | -14.84% | ||
| Current year | -24.00% |
| 1 week | 9.06 |  | 9.6 |
| 1 month | 8.57 | | 9.66 |
| Current year | 8.57 | | 13.48 |
| 1 year | 8.57 | | 14 |
| 3 years | 8.57 | | 21.45 |
| 5 years | 8.57 | | 44.67 |
| 10 years | 4.08 | | 45.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 01/11/2005 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 30/06/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 29/01/2018 |
Susan Smith
BRD | Director/Board Member | - | 23/09/2019 |
| Chairman | - | 01/01/2024 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.73% | 0.00% | -12.56% | -52.03% | 348M | |
| -0.97% | +0.53% | +24.77% | -4.23% | 72.53B | |
| -0.08% | +2.69% | +55.60% | +178.31% | 53.4B | |
| +2.77% | +44.90% | +44.90% | +44.90% | 44.97B | |
| +0.72% | -18.28% | -58.91% | -68.18% | 34.1B | |
| -6.43% | -0.01% | +58.98% | -38.19% | 28.25B | |
| -0.77% | +3.07% | +108.28% | -61.31% | 19.85B | |
| -1.20% | -0.14% | +59.63% | +49.56% | 19.5B | |
| -4.67% | -8.22% | +65.37% | +106.24% | 19.21B | |
| +0.39% | +1.33% | +43.74% | +85.61% | 16.23B | |
| Average | -1.09% | -2.03% | +38.98% | +24.07% | 30.84B | |
| Weighted average by Cap. | -0.73% | -1.93% | +37.99% | +35.64% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 99.5M 71.87M 61.57M 56.3M 53.31M 98.71M 6.87B 672M 261M 3.27B 270M 264M 11.37B | 105M 76.12M 65.21M 59.63M 56.46M 105M 7.28B 712M 276M 3.46B 286M 280M 12.04B |
| Net income | 35.94M 25.96M 22.24M 20.33M 19.25M 35.65M 2.48B 243M 94.25M 1.18B 97.41M 95.33M 4.1B | 38.23M 27.62M 23.66M 21.63M 20.49M 37.93M 2.64B 258M 100M 1.25B 104M 101M 4.37B |
| Net Debt | -254M -183M -157M -144M -136M -252M -17.52B -1.71B -666M -8.33B -688M -673M -28.98B | -286M -207M -177M -162M -153M -284M -19.76B -1.93B -750M -9.39B -776M -759M -32.68B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/05/26 | 9.470 $ | -0.73% | 48,828 |
| 14/05/26 | 9.540 $ | +2.03% | 30,986 |
| 13/05/26 | 9.350 $ | -0.11% | 50,038 |
| 12/05/26 | 9.360 $ | -2.50% | 69,973 |
| 11/05/26 | 9.600 $ | +1.37% | 92,008 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CUV Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition